THE BRITISH ONCOLOGY PHARMACY ASSOCIATION
REPORT AND ACCOUNTS
FOR THE YEAR ENDED
31" MARCH 2024
REGISTERED CHARITY NO. 1065026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
CONTENTS
Trust Information
Independent Examiner's Report
Trustees Annual Report
Recelpts and Payments Account
Statement of Assets and Liabllities
14

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
TRUST INFORMATION
Registered Charity No.
1065028
Trustees
Robert Duncombe
Emma Foreman
Joseph Williams
Treasurer
Anish Tailor
Dharmisha Chauhan
Shumi Tattersfield
Independent Examiner
Barry Fine
Address
clo GBH Law,
718 Innovation Place,
Douglas Drive
Godalming,
Surrey GU7 1JX
Bankers
National Westminster Bank plc

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPf'
I report on the Accounts of the Association for the year ended 31$1 March 2024 which are set out on pages
12-14.
Respectlve Responslbllltles of the Trustees and Examlner
The charity's trustees are responsible for the preparatlon of the accounts.
The charity's trustees consider that an audit is not required for this year under section 144 of the Charities
Act 2011 (the Charities Act) and that an independent examination is needed.
It is my responsibility to:
examine the accounts under section 145 of the Charitles Act,
to follow the procedures laid down in the general dlrectlons given by the Charity Commisslon
{under section 145{5){b}} of the Charities Act, and
to state whether particular matters have come to my attention.
Basls of Independent Examlner's Report
My examination was carried out in accordance with the General DIre￿lonS given by the Charity
Commissioners. An examination includes a review of the accounting records kept by the charity and a
comparison of the accounts presented with those records. It also includes consideration of any unusual
items or disclosures in the Accounts, and seeking explanations from the trustees concerning any such
matters. The procedures undertaken do not provide all the evidence that would be required in an audit,
and consequently no opinion is given as to whether the accounts present a Irue and fair, view and the
report is limited to those matters set out in the statement below.

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
Independent Examiner's Statement
In connection with my examination, no matter has come to my attention:
which gives me reasonable cause to believe that in any material raspact the requirements
a. to keep accounting records in accordance with Section 130 of the Charities Act, and
b. to prepare Accounts which accord with the accounting records and comply with the
accounting requirements of the Charities Act.
have not been met; or
2)
to which, in my opinion, attention should be drawn in order to enable a proper understanding
of the Accounts to ba reach8d,
Nam8.
B. Fino FCA
Address Parkgates
Bury New Road
Prestwich
Greater Manchester
M25 OJW
Signed.
Dated... .<..11

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
BOPA is an unincorporated organisation governed by its constitution.
Charity Number 1065026
Administratlve Details
Principal address: 39 Oakley Road, Luton, Bedfordshire, LU4 9PT
Member
Role within BOPA
Date enacted
Joe Williams
Shereen Nabhani-Gebara
Emma Foreman
Jess Pealin
Chair
Vice Chair / EDI Co-chair
Past Chair
Secretar
Co-secretary Elect I Ind
Sector Rep l Digital Co-
Chair
Co-secretary Elect / E&T
Co-chair I Podcast
Treasurer
Treasurer
Co-Treasurer Elect
Technician Re
Industr
Re
GAP Co-chair
EDI
osium 110 Co-chair
Se
tember 2023
Clayton Wong
September 2023
Michal Sladkowski
September 2023
Dharmisha Chauhan
Anish Tailor
Shumi Tattersfield
Mollie Bisho
Colm Dood
Rhiannon Walters-Davies
Nisha Shaunak
Alice Tew
tember 2023
Structure
Members of the committee are elected for a three year term of office by the voting members through an
electronic ballot. Each candidate provides a written statement in support of their application. These
statements are electronically submitted to the members. The results of the eleclion are announced at the
Annual Symposium. Members can serve a maximum of two consecutive terms of office on the committee.
This committee then votes for the officers of Chair and Treasurer between Ihemselves.
The association does not require any fundraising or grant-making activities. It is self-funding by members
subscriptions, with additional sponsorship from the pharMa￿Ut1¢al industry for key projects such as e-
Learning,

Decisions are made at the monthly committee meetings on behalf of the membership. The committee
have several sub committees which feed back to the committee their decisions and ideas on behalf of the
membership.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
Sub committees:
1. Annual Symposium
2. Education and Training
3. Research
4. Community and Primary Care Phannacy
5. Dig ital
6. Guidelines, Advocacy and Publications
7. Pharmacy Technician
8. Workforce and Capacity
9. Equity, Diversity, and Inclusion
Governance
Due to the nature of this charity no policies are In place to recruit and train trustees. Generally, those
people elected by the members of the association are then responsible for the maintenance and safe
handling of the Charity on behalf of the members.
Any decisions that require the m8mbership to be Involved in, such as national consultation documents,
the document is placed on the BOPA website and emailed throughout the membership for comments to
be received by the reference sub-committee who will then collate the response and return it.
The association works closely wilh the NHS England Cancer Area Team Pharmacists, and other relevant
(oncology) pharmacy groups.
Objectlves
The stated alm of BOPA is to promote excellence In the pharmaceutical care of patients with cancer
through education, communication, research and innovation by an alliance of hospital, community and
academic phannacists, phamiacy technicians, those in the pharmaceutical industry and other healthcare
professionals.
Publlc Beneflt
These activities are undertaken to further the charitable purposes for the public benefit and the trustees
believe that these activities satisfy the charity commissions general guidance on public benelit.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
Achlevements and performance
The role of BOPA in supporting and provided educational and training resources has increased and the
scope and breadth of the projects and advocacy roles we have been involved with has widen. In light of
this we have seen our BOPA membership increasing, for example in September 2024 we had 925 paid
members, 1928 free members and 31 corporate members. Additionally, since the launch of the website
in 2019, BOPA has received over 2000 networking and clinical queries. Examples of BOPA'S key
achievements are described below.
October 2023 saw the launch of L£t's Communicate Cancer 2, Play Your Part and the new BOPA and NPA Cancer
Hubs. The underlying aim of the sub-commitiee this year was to allow space to refocus following Such major pn)ject
work. This year h&s seen the transfer of the Let's Communicate Cancer maintenance role be overseen by the BOPA
Education and training sub-committee. A full review of content was due at the 3 year post launch point. A special
interest group called CASPC - Community Approach io Advanced Cancer Support has been fonned. This group is
currently beeking funding to cary out areas of work linking primary and secondilly care in the care of canc¢rpalients.
The digital sub-has been v8ry busy supportlng and promoting various evants with a variety of webslte
uploads and communications from other sub-committees including:
Research webinar sessions
EDI webinar sessions
Education &Training webinar sessions
Let's Talk About SACT - a BOPA Podcast
Introduction to Oncology Course
Updates to Let's Communicate Cancer
Uploading new resources I policies
E learning modules 8.g. UTIC, Introduction to Immuno-oncology, Level 1 training
Conference promotion
Promoting research surveys
Communication of all important updates In the cancer care community
Webslte updates:
#BOPA2023 Conference videos uploaded on to websit8
Launch of new SACT verification hub page BOPA SACT Verification HUB - BOPA
Development of Memberships FAQ section BOPA membership FAQS - BOPA
Member search updated
Member profiles now include Orchid ID/google scholar
Agreement for code of conduct for BOPA now a requirement within the membership
Member group pages updated to include 'circles' _ improving aesthetics
Pop up added to website for free associate members to illustrate the benefits of full membership
Regular website maintenance
Trello board subscription to help organise the workload of each of the subcommittees

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
The research sub-committee continues to host research webinars to ensure more phannacy professionals
engage and feel confident to conduct their own research projects and the research mentor support
programme which started last year continues. To support pharmacy professionals in research, the
subcommittee hosted 5 webinars. During the period of 23124, we hosted seven webinars. Our hour long
webinars, take place every 6-8 weeks at diff erent times and on different days of the week to ensure
accessibility. We invited BOPA members and external speakers to present at the 202312024 webinars:
1. Shared experience from SIOG pharmacy interest group
2. BOPA symposium 2023 poster discussion
3. UK Early Career Researchers Can￿r Group
4. A DPharm journey
5. Real world experience of bispecific antibody Teclistamab in relapsed refractory multiple myeloma
6. A survey on understanding the gaps in SACT education to minority group cancer patients
7. Understanding global participation in gynae-oncology RCTS: a syslematic review approach
8. Vulnerable groups as caregivers {women, LGBTQ, Indigenous populations)
In addition to the webinar the research committee we received 155 abstracts for the 2024 conference.
Five were selected for oral presentation (Plenary) on 12th Oct 2024, five for the highly commended
poster presentations on 12th Oct 2024, 121 abstracts ac￿pted for poster presentation and 24 were
rejected. We have added a new category 'Servico improvement and new Models of Care, for the 2024
conference. All oral presenters have been invited to present at our My Research Webinar in 2025.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
The education and training team continued to deliver high quality education and training reSoUr￿s, key
worked centered on the areas below:
E-Learning
Breast Can￿r, lower Gl, melanoma, and lung cancer modules have
now been released with positive feedback.
Myeloma and CINV have been commissioned. With the aim of
completion before the end of 2024.
Immunotherapy eLearning has also been published.
Created wider sub-committee to manage ongoing passport
developments.
Representation from England, Scotland and Wales.
Phamacists and technicians involved in updat8.
New materials for core module; UTIC,10 eLearning.
Successful uptake across the 4 nations.
Positive feedback for the Core Module.
Interest spanning beyond the UK.
Preparing for BOPA symposium.
Ready to ask the membership to contribute new content
Work plan for the next year based on needs is underway.
New Scientist Publication here: tinyurl,com/mrykyvkz
Two successful evenls in the last year..
London Nov 2023 (80 delegates)
Leeds March 2024 (60 delegates)
Demand continues to be high - fully booked for London Nov 2024 (80
delegates)
NEW session for 2024 on Genomics - great feedbackl
Partnership agreed with Media1 for 2025 to support event
manag8m8nt
NeJLagenda (based on delegate feedback) to be launched for events
in 2025
Organised, hosted and co-ordinated 15 webinars
•Over 350 registrants and 400 playbacks
•Collaborations with national and international organisations and cancer
charities including: APOPA
CAPhO
COSA
ECO
HOPAK
Isopp
NCODA
OUTPATIENTS
SIOG
SOBRAFO
UK ECRC
BOPA Passport
Introduction to
Oncology
Webinars
10

•Topic Highlights..
Celebrate Pride Month
Highlight from international conferences
ISOPP Global Drug Shortages Webinar
•2025:
You Ask, We Listenl
The equity, diversity and inclusion subcommittee has been very active in the past 12 months in delivering
BOPA'S commitment to building a diverse, equitable and inclusive community for all members, non-
members and patients in cancer care.
Key Achievements for the past 12 months
Cllnlcal conslderatlons for the safe and
This work is In collaboration with OutPatients
Incluslve prescrlblng for trans gender and (a charity supporting and amplifying LGBTIQ+
non-blnary patlents
voices in cancer carel
The TRANScribing guideline Is now available
on BOPA website and -OOUTpatients website
Safe and supportive prescriblng in transgender
and non-binary patients with cancer is
PUBLISHED on the British Pharmacological
Society Journal
Collaborations with NHSE to develop
factsheets on care for transgender and non-
binary patients. First Transgender Factsheet
PUBLISHED, more factsheets to come
Best practice principles for inclusive care of
transgender and non-binary patients is now
available on the Pharmaceutical Journal
PJ article
Collaborations wlth European Cancer
Organization for wider exposure in Europe
Equity, diversity, and inclusion in oncology
pharmacy practice.. Everyone's business.
PUBLISHED in the Journal of Oncology
Pharmacy Practice
Championing equity, diversity and inclusion
{EDI} to support the pharmacy workforce and
provide inclusive care
Oncology Professional Care- May 2024
UK Oncology Forum - June 2024
Presentation on TRANScribing guideline has been arranged with Gilead Australia in October
2024
The American Society of Consultant Pharmacists September issue citing the TRANScribing
guideline
Publicatlon
Dlssemlnatlon
BOPA advocacy & vislblllty

Inclusive patlent Care
EDI projects completed in 2024.
LD & cancer part 1 completed- accepted for
BOPA Conference 2024
Inclusive counselling for ethnic minority groups
manual script in preparation
Advocacy & empowement- accepted for
BOPA Conference 2024
Role of pharmacy in the care of older patients
accepted for BOPA Conference 2024 and
International Society ol Geriatric Oncology
{SIOG) presentation 2024
Role of pharmacy in supporting families of
children with cancer- accepted for BOPA
Conference 2024
Interventions to optimise care for people from
minority and ethnic groups - manual script in
preparation
To mark Pride Month, we collaborated with the
E&T committee to organise a session on
providing LGBTlQ+ Inclusive Care
Code of conduct policy has b8en implemented
before memb8rship application and renewal
Complaint procedure is put in place lo enab16
EDI related concerns to be raised and
managed accordingly. Lessons learnt can be
implemented to ensure BOPA and its
members embrace EDI principle and culture
This year, there are 4 topic streams within the
conference programme to address equity,
diversity and inclusion in oncology practice
EDI checklist for inclusive counselling:
Physical disability
Ethnicity & Age
Learning disabillty
Neurodiversity
Educatlonal Weblnar
Code ol Conduct, EDI Complalnt pollcy &
Complalnt lorm
Conlerence
Further projects underway
Members follow-up survey to evaluate
engagement interests
Cultural calendar - strategy to highlight
themes
EDI podcasts in 2025
THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
12

This year has been highly productive for GAP members, who have engaged in a variety of projects
spanning the full range of BOPA activities. We will continue to provide governance oversight within BOPA,
ensuring clarity and accountability for the membership, and for BOPA'S engagement with external
organisations, ensuring that collaborations represent the best interests of BOPA, its members, and the
wider oncology pharmacy profession. We remain committed lo advocating for the role of phannacy
professionals within can￿r services and promoting the excellent work undertaken by BOPA and its
members. Additionally, we will continue to publish position statements on behalf of the BOPA
membership, ensuring that we speak as one body on critical issues in oncology pharmacy, providing
support and guidance as needed.
A summary of the activities of the committee are summarised below..
Declaratlons of Interests
The GAP committee continue to ensure appropriate governance of the BOPA Executive and Sub
Committees by undertaking annual reviews of the declarations of interests from those required as per
policy.
Fellowshlp Scheme
The GAP committee continue to have oversight of the Fellowship Scheme within BOPA.
SACT Consent
The GAP committee has contributed to this multi-agency report to help provide guidance and support to
provider organisations in the context of SACT consent.
UK SACT Board- Intrathecal Pollcy Update
The GAP committee has contributed to the ongoing UK SACT Board update of this guidance to ensure
that professional guidance remains relevant for in this critical area.
BOPA Vlslon and Strategy
The GAP committee members have worked closely with the members of th8 pillars of the BOPA Vlslon
and Strategy to ensure that appropriate governance frameworks are adhered to.
UK SACT Board - Guldance on the management of anaphylaxls and hypersensltlvlty reactlons In
patlents recelvlng Intravenous systemlc antl-cancer therapy
The GAP committee has contributed to the ongoing UK SACT Board update of this guidance to ensure
that professional guidance remains relevant for in thls critical area of oncology therapy.
13

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
The symposium sub-committee had another productive year and delivered another successful conference
in Wales in 2023 alongside the executive committee and our sponsors. Thank you to all involved.
2023 Statistlcs:
6th to the 8th October 2023, ICC Wales
Attendance - 581 including exhibitors and 371 no exhibitors
45 exhibitors
We received 113 abstracts for the 2023 Symposium. 5 were selected for Oral presentation
(Plenary), 5 for the highly commented poster presentations, 86 for posters and 17 were rejected. There
was 1 abstract received under the setvice improvement and New Models of Care category which was
selected for oral and poster presentation.
Research Publication is now available in JOPP - Journal of Oncology Pharmacy Practice - Volume SO,
Number 1_suppl, Feb 01, 2024 {sagepub.com)
Our annual symposium continues to be our biggest educational and networking event of the y&ar.
Beneflt to the publlc
As an organisation promoting eX￿llenCe in the pharmaceutical care of patients with Can￿r, BOPA
provides up-to-date resources for academic pharmacists, pharmacy technicians, those in the
pharmaceutical Industry and other healthcare professionals. Thereby promoting up-to-date safe and
eff icient practice through education, training and through participating in collaborative research both
nationally and at a global level.
Actlvltles undertaken lo beneflt the publlc
1. Let's Communicate Cancer project. The aim of the project is to educate and up-skill community
pharmacists to engage with the public in the community setting with confidenc8 and developing a
knowledge base around cancar and its treatments.
2. The development of podcast to provide education and training using a new technology platform.
3. Annual BOPA symposium: Providing educational sessions to our members, on areas such as
clinical management in cancer, good practice ￿search methods (e.g., engaging with patients,
public and carers) and sci&ntific updates. This ensures our members have the knowledge, skills,
and confidence to manage and work with cancer patients at their place of work.
4. The publication of the Clinical considerations for the safe and inclusive prescribing for trans
gender and non-binary patients" This work was complated in collaboration with OutPatients (a
charity supporting and amplifying LGBTlQ+ voices in cancer care).
14

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
Financlal revlew
Trusteeslmembers expenses for services
As a charitabl8 organisation members and trustees are eligible for travel expenses, team building
exercises and hotel accommodation. In this financial year the total cost is £3,866.
In this financial year meetings- have continued to moved back to face to face meetings post-COVID-19
Reserve accounts
The Charity holds cash funds of £163,295 split be￿een a Nat West Bank account and a Scottish Widows
account of which £92,086 are restricted.
The reason for holding these reserves is:
1. In the 8vent of a reduction in income the charity will be able to continue to provide its core functions
and cov8r all existing fixed costs and commitments e.g., website maintenance.
2. The charity provides an annual educational event. In the normal course of events these meetings
are at least'break even" However, there is the risk that the income for this meeting may be below
the costs associated with running the meeting, and BOPA will be liable for this shortfall.
Summary ot accounts
The total income received was £166,227 and the total payments rnade were £257,186.
This giving BOPA a negative areas for the year of £90,959 and total assetslfunds of £163,295 split
between unrestricted of £71,209 and restricted funds of £92,086.
Plans for the future
1 . To continue to collaborate with national and international (oncology) phannacy groups to maintain
and consolidate its professional and advocacy role.
2. During 2024-2025 BOPA will continue to develop and provide high quality education and training
materials for all their members.
3. BOPA is also keen to develop educational scholarships for its members and to fund research into
Pharmacy Practice Research where there is a focus on cancer.
4. The BOPA 2024 symposium will be delivered as a face-to-face in Birmingham, England.
15

THE BRrrisH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
Declaration
Signed on behalf of the charity's trustees
Signature
Full Name
Mr Joseph Williams
Position
Chair
Date
0810112025
Signature
Full Name
Ms Shereen fraDhani-Gebara......................................................
Position
Vice -chair
Date
0810112025
Signature
Full Name
Mr Rob Duncombe
Position
BOPA Trustee
Date
0810112025
16

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
IXWA 311C(V24
T.Ir2A
r2A
nvr.rlpiy'
IDtrtv*t
J74
Ircr LC¢
1.078
rAL¢wtJ EIMr
ChSPCC
Irictrtr Isopi)
IW¢:hr. ISO
Jts.L
Ilrltsiul Pkn.r* ￿qu,￿￿ ir•lttl
ts.10
IIOI>A (•raAt
Jo.0
I"¥rtUl1v￿ Irvwl
>.IVJ
?4.7
a.X#) ?A.Y41 ￿7
?.1
411?
<.'UUnl¥i
?d7
Stctrf•rlwt
l¢ rey¢•i¢li
1.ou¢411wi LCC
7.010
?.030
7.7x1 69.1))5
10.IAry
.Ido
t Intto to QThL
Llle lil Iri Ihty
¢Tr
1?.7
1?.7
Lr.LiJL fev.¥
?.ti7S
p•%¥port
ury
lyr1￿ rnty
Ca*h tsr￿L￿t forAxi
1.7J6 2￿1.￿4 71&769
17

THE BRrrisH ONCOLOGY PHARMACY ASSOCIATION (BOPA)
BOPA summary-yle 31103124
Statement of assets and liabilities
2023124 2022123
60960
153064
18819
18569
83516
82621
Nat West current
Nat West reserve
Scottish Widovrfs
254254 163295
The Accounts were approved by the Committee on 22 January 2025
Joseph Williams -
Chalr
Shereen Nabhani-Gebara - Vice-chair
'Dharmisha Chauhan
Co-Treasurer
Anish Tailor Co-Treasurer
18